THe is rekindling the results of a new study into a debate among cardiologists about whether a prescription fish oil product, vasepa, reduces patients’ risk of heart attacks and strokes.
The study does not test vasepa made by Amerson Corp., but another drug called apanova, made by AstraZeneca. But this new trial, called Strength and presented Sunday at a virtual meeting of the American Heart Association, was completely negative, while Vasuspa’s first test, called REDUCE-IT, showed that Wassepa had heart attacks, strokes and Reduces cardiac death by 25%. The vote was not unanimous when the Food and Drug Administration panel voted on whether Wasepa was given broad approval last year. Many cardiologists are struggling to find out what gives.
Unlock this article by subscribing to STAT + and enjoy your first 30 days!
get started
What is this?
STAT + is STAT’s premium subscription service for in-biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers policy developments, early science breakthroughs and clinical trial results in Wall Street, Washington, and news on healthcare disruptions in Silicon Valley and beyond.
what is included?
- Daily Reporting and Analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newspaper to brief you on the most important industry news of the day
- State + chat
- Weekly opportunities to engage with our correspondents and leading industry experts in live video conversations
- Special industry events
- Premium access to customer-only networking events across the country
- Best journalist in the industry
- The most reliable and well-connected newsroom in the health care industry
- and many more
- Exclusive interviews with industry leaders, profiles and premium tools like our CRISPR Trackr.